Shilpa Medicare Limited (SHILPAMED) — Announcement

1 Announcement Neutral 📄 PDF

Shilpa Medicare announced that its subsidiary Shilpa Biologicals settled a legal dispute with Sartorius Stedim India by paying Rs.9 million in court-ordered settlement, resolving claims of Rs.20.13 million plus interest. The agreement was executed on 23 June 2026 before the XI Addl. City Civil and Sessions Court in Bengaluru, with minimal financial impact limited to the settlement amount. This action satisfies SEBI disclosure requirements under Regulation 30.

2 Announcement Neutral 📄 PDF

Shilpa Biologicals, a material subsidiary of Shilpa Medicare Limited, has commissioned a state-of-the-art GMP manufacturing facility for Antibody-Drug Conjugate (ADC) drug substance in Dharwad, India. The facility is fully operational and undergoing GMP qualification, positioning the company as a cost-competitive CDMO partner for global oncology innovators. This marks a strategic expansion into integrated ADC manufacturing, leveraging over 25 years of high-potency API expertise to offer end-to-end solutions from payload synthesis to final drug substance purification.

📊 Stock Analysis — SHILPAMED ✨ Ask AI About This